Pacific Biosciences is trading at $1.64 (+7.67%) as the stock stages a sharp rebound from the previous session's selloff.
- The recent downward pressure followed a mixed Q1 2026 report where the company beat EPS expectations but missed on revenue.
- Management lowered the high end of its 2026 revenue guidance to a range of $165 million-$175 million.
- With no fresh catalysts reported today, the price action appears to be a technical recovery in the volatile small-cap biotech sector.